Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors.

ABSTRACT:

Background

CD40 agonist immunotherapy can potentially license antigen-presenting cells to promote antitumor T-cell activation and re-educate macrophages to destroy tumor stroma. Systemic administration of CD40 agonists has historically been associated with considerable toxicity, providing the rationale for development of tumor-targeted immunomodulators to improve clinical safety and efficacy. This phase I study assessed the safety, tolerability, preliminary antitumor activity, and preliminary biomarkers of ABBV-428, a first-in-class, mesothelin-targeted, bispecific antibody designed for tumor microenvironment-dependent CD40 activation with limited systemic toxicity.

Methods

ABBV-428 was administered intravenously every 2 weeks to patients with advanced solid tumors. An accel

SUBMITTER: Luke JJ 

PROVIDER: S-EPMC7898862 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature